By Susan Comninos NEW YORK (Reuters Health) Oct 14 –
MacroChem Corp. said on Friday that US regulators have halted trials of the firm’s topical drugs containing SEPA because of concerns about the absorption-enhancer’s potential to cause cancer.
The clinical hold halts all new development of MacroChem’s entire pipeline until the matter is resolved. MacroChem has not yet commercialized any SEPA-based products.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!